Jefferies Financial Group’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-105,755
Closed -$2.55M – 1377
2026
Q2
$2.55M Buy
105,755
+1,394
+1% +$42.3K 0.02% 607
2026
Q1
$3.17M Buy
+104,361
New +$2.78M 0.02% 457
2024
Q2
– Sell
-10,600
Closed -$72K – 1451
2024
Q1
$72K Buy
+10,600
New +$51.3K ﹤0.01% 1471

Other funds holding CAPR

Jefferies Financial Group's CAPR Position: Q3 2026 in Review

Jefferies Financial Group sold out of Capricor Therapeutics (CAPR) in Q3 2026, closing a stake of 105,755 shares — an estimated $2.55M sold.

Jefferies Financial Group first reported a position in CAPR in Q1 2024 and held it in 3 quarters. The position peaked at $3.17M in Q1 2026. 158 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Jefferies Financial Group reported no remaining Capricor Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 105,755 Capricor Therapeutics shares in Q3 2026, an estimated $2.55M.
  • Jefferies Financial Group first reported a position in Capricor Therapeutics in Q1 2024 and held it in 3 quarters.
  • Jefferies Financial Group's Capricor Therapeutics position peaked at $3.17M in Q1 2026.
  • 158 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.